Erythropoietins and Erythropoiesis
DOI: 10.1007/3-7643-7543-4_14
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies to endogenous and recombinant erythropoietin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 17 publications
1
2
0
Order By: Relevance
“…Development of anemia secondary to neutralizing antibody formation was observed in these animals similar to what was reported in the renal transplant patients (Piercy et al, 1998;Mayeux and Casadevall 2003). A similar reaction was also observed in rhesus monkeys dosed with a hybrid molecule containing recombinant human EPO (Coscarella et al, 1998).…”
Section: Immunogenicity Data From Non-clinical Studiessupporting
confidence: 78%
See 1 more Smart Citation
“…Development of anemia secondary to neutralizing antibody formation was observed in these animals similar to what was reported in the renal transplant patients (Piercy et al, 1998;Mayeux and Casadevall 2003). A similar reaction was also observed in rhesus monkeys dosed with a hybrid molecule containing recombinant human EPO (Coscarella et al, 1998).…”
Section: Immunogenicity Data From Non-clinical Studiessupporting
confidence: 78%
“…The association of recombinant human erythropoietin (EPO) treatment, specifically Epoetin alpha, with pure red cell aplasia (severe anemia) in chronic renal failure patients has been directly attributed to the development of anti-EPO antibodies that cross-react with endogenous EPO (Casadevall et al, 2002). The sudden increase in the incidence of neutralizing antibody development to EPO has been attributed to a change in the formulation, besides other causes (Mayeux and Casadevall, 2003). This has heightened the concerns significantly around product quality, handling, transport and storage, and on product delivery mechanisms.…”
Section: Breakdown Of Immune Tolerancementioning
confidence: 99%
“…In rare cases, antibodies to administered rHuEPO are produced in patients which also recognize and neutralize endogenously produced EPO, resulting in the development of antibody mediated pure red cell aplasia (PRCA) 57. Although extremely rare before 1998, with only three cases being reported, by 2003 there were over 160 patients worldwide diagnosed with antibody‐positive PRCA after receiving rHuEPO with the majority of cases outside the USA 58. Since millions of patients had been treated with rHuEPO prior to 1998, it was hypothesized that changes in the manufacturing procedure and or formulation may have accounted for this increase 57…”
Section: Properties Of Glycosylated and Glycoengineered Proteinsmentioning
confidence: 99%